The Federal Commission for Protection against Health Risks (Cofepris) reports that, according to the latest biweekly report on therapeutic extensions, 149 healthcare inputs have been authorized in the categories of drugs, medical devices and clinical trials.

In the report for the first half of June, 25 drugs were authorized, including efavirenz/lamivudine/tenofovir disoproxil fumarate, a new molecule for the treatment of HIV, and L-asparaginase, a biotech for acute lymphoid leukemia.

In addition, 116 new medical devices were registered, of which 21 are for medical care, including: hearing aids; a closed wound drainage system; an osteosynthesis plate and screw system; and total knee and shoulder replacements. In addition, 35 are medical equipment, including a subdural anesthesia kit; blood glucose meters; a flexible videolaryngoscope; and hip replacement instruments. Finally, 60 are intended to measure glycated hemoglobin, liver function, hormones, copper, zinc, p24 antigen for the detection of HIV, tetanus toxin, trypanosoma cruzi, and rheumatoid actor, among others. Read more about it here

If you need more information on drug regulatory issues ELS can certainly help you with our registration services for your products

Please contact your ELS local consultant or through the email:

Contact us

We will contact you as soon as possible.